uid
stringclasses 10
values | dataset_id
stringclasses 1
value | year
int64 2.02k
2.02k
| therapeutic_area
stringclasses 6
values | program_stage
stringclasses 1
value | efficacy_signal_present
stringclasses 2
values | safety_margin_ok
stringclasses 2
values | biomarker_support
stringclasses 2
values | target_validity
stringclasses 3
values | portfolio_fit
stringclasses 2
values | team_narrative_strength
stringclasses 10
values | question
stringclasses 1
value | ground_truth_label
stringclasses 2
values | ground_truth_rationale
stringclasses 10
values | outcome_signal
stringclasses 2
values | source_citation
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GN-TR-001
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,024
|
Oncology
|
Phase2
|
yes
|
yes
|
yes
|
strong
|
yes
|
Narrative matches data and portfolio need.
|
Should program proceed. Answer go or no_go.
|
go
|
Aligned biology and signal.
|
advance
|
Synthetic
|
GN-TR-002
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,024
|
Oncology
|
Phase2
|
no
|
no
|
no
|
weak
|
no
|
Narrative optimistic despite weak data.
|
Should program proceed. Answer go or no_go.
|
no_go
|
Weak efficacy and safety.
|
terminate
|
Synthetic
|
GN-TR-003
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,023
|
Cardiology
|
Phase2
|
yes
|
yes
|
yes
|
strong
|
yes
|
Signal consistent across endpoints.
|
Should program proceed. Answer go or no_go.
|
go
|
Consistent efficacy and safety.
|
advance
|
Synthetic
|
GN-TR-004
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,023
|
Cardiology
|
Phase2
|
no
|
yes
|
no
|
medium
|
no
|
Marginal efficacy and no biomarker support.
|
Should program proceed. Answer go or no_go.
|
no_go
|
Insufficient benefit.
|
terminate
|
Synthetic
|
GN-TR-005
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,022
|
Neurology
|
Phase2
|
yes
|
yes
|
yes
|
strong
|
yes
|
Clear responder subgroup.
|
Should program proceed. Answer go or no_go.
|
go
|
Signal in enriched population.
|
advance
|
Synthetic
|
GN-TR-006
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,022
|
Neurology
|
Phase2
|
no
|
no
|
no
|
weak
|
no
|
No clinical improvement.
|
Should program proceed. Answer go or no_go.
|
no_go
|
No signal present.
|
terminate
|
Synthetic
|
GN-TR-007
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,021
|
Rheumatology
|
Phase2
|
yes
|
yes
|
yes
|
strong
|
yes
|
Dose response and safety acceptable.
|
Should program proceed. Answer go or no_go.
|
go
|
Aligned package.
|
advance
|
Synthetic
|
GN-TR-008
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,021
|
Rheumatology
|
Phase2
|
no
|
yes
|
no
|
weak
|
no
|
Minimal improvement.
|
Should program proceed. Answer go or no_go.
|
no_go
|
No meaningful efficacy.
|
terminate
|
Synthetic
|
GN-TR-009
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,020
|
Infectious Disease
|
Phase2
|
yes
|
yes
|
yes
|
strong
|
yes
|
Strong pathogen clearance.
|
Should program proceed. Answer go or no_go.
|
go
|
Clear benefit.
|
advance
|
Synthetic
|
GN-TR-010
|
pharma-program-go-no-go-coherence-risk-v0.1
| 2,020
|
Metabolic
|
Phase2
|
no
|
no
|
no
|
weak
|
no
|
No glucose control improvement.
|
Should program proceed. Answer go or no_go.
|
no_go
|
No efficacy.
|
terminate
|
Synthetic
|
What this repo is for
support go or stop decisions in drug programs
detect when teams continue weak assets
detect when strong assets are wrongly killed
align biology, safety, and signal with decision
reduce sunk-cost bias
support portfolio governance boards
support licensing and diligence reviews
How it is used
You provide one row describing a program.
The system returns one label.
go or no_go
How to read the output
go means
efficacy signal present
safety acceptable
biomarker supports
target valid
dose workable
narrative matches data
no_go means
weak or absent efficacy
safety margin poor
biomarker not predictive
target weak
narrative stronger than evidence
continuation driven by momentum
Who uses it
portfolio committees
clinical leadership
translational teams
investors
due diligence teams
- Downloads last month
- 12